Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Total Current Liabilities (2016 - 2025)

Syndax Pharmaceuticals has reported Total Current Liabilities over the past 11 years, most recently at $120.1 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $120.1 million for Q4 2025, up 16.0% from a year ago — trailing twelve months through Dec 2025 was $120.1 million (up 16.0% YoY), and the annual figure for FY2025 was $120.1 million, up 16.0%.
  • Total Current Liabilities for Q4 2025 was $120.1 million at Syndax Pharmaceuticals, up from $114.2 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for SNDX hit a ceiling of $120.1 million in Q4 2025 and a floor of $20.7 million in Q4 2021.
  • Median Total Current Liabilities over the past 5 years was $35.0 million (2022), compared with a mean of $52.9 million.
  • Biggest five-year swings in Total Current Liabilities: dropped 27.55% in 2022 and later soared 166.03% in 2025.
  • Syndax Pharmaceuticals' Total Current Liabilities stood at $20.7 million in 2021, then surged by 40.53% to $29.1 million in 2022, then soared by 99.88% to $58.1 million in 2023, then soared by 78.24% to $103.5 million in 2024, then grew by 16.0% to $120.1 million in 2025.
  • The last three reported values for Total Current Liabilities were $120.1 million (Q4 2025), $114.2 million (Q3 2025), and $113.0 million (Q2 2025) per Business Quant data.